西妥昔单抗
无容量
医学
头颈部癌
肿瘤科
生物标志物
内科学
临床试验
癌症
临床研究阶段
头颈部
放射治疗
毒性
总体生存率
头颈部鳞状细胞癌
作者
Ritu Chaudhary,Graydon Moorhead,Robin Park,Jiannong Li,Michael J. Schell,Xiaofei Song,Aik Choon Tan,Robbert J.C. Slebos,Maria I. Poole,Samuel S. Freeman,Sowjanya Thatikonda,Yeva Meshkovska,Juan C. Hernandez‐Prera,Kedar Kirtane,José A. Guevara-Patiño,Antonio L. Amelio,James W. Rocco,Brian P. Danysh,Marcelo Bonomi,Nabil F. Saba
标识
DOI:10.1158/1078-0432.ccr-25-2201
摘要
Our long-term follow-up study indicates that the combination of cetuximab and nivolumab is efficacious and tolerable and that patients with p16-negative R/M HNSCC may have greater benefit from this combination.
科研通智能强力驱动
Strongly Powered by AbleSci AI